Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Change in Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Gain on revaluation of warrants issued in May 2019 financing and December 2015 financing	$ 4,430	$ (681)	$ 6,045	$ (162)
Loss on modification of December 2015 warrants	0	$ 0	257	$ 0
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance			585
Initial fair value of warrants issued in conjunction with May 2019 financing			7,334
Gain on revaluation of warrants issued in May 2019 financing and December 2015 financing			(6,045)
Loss on modification of December 2015 warrants			257
Gain on revaluation of contingent liabilities			0
Ending Balance	2,131		2,131
Contingent Success Fee Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance			34
Initial fair value of warrants issued in conjunction with May 2019 financing			0
Gain on revaluation of warrants issued in May 2019 financing and December 2015 financing			0
Loss on modification of December 2015 warrants			0
Gain on revaluation of contingent liabilities			(19)
Ending Balance	$ 15		$ 15